NO971900L - Mixtures and treatment of multiple sclerosis - Google Patents

Mixtures and treatment of multiple sclerosis

Info

Publication number
NO971900L
NO971900L NO971900A NO971900A NO971900L NO 971900 L NO971900 L NO 971900L NO 971900 A NO971900 A NO 971900A NO 971900 A NO971900 A NO 971900A NO 971900 L NO971900 L NO 971900L
Authority
NO
Norway
Prior art keywords
disease
multiple sclerosis
treatment
autoantigen
myelin
Prior art date
Application number
NO971900A
Other languages
Norwegian (no)
Other versions
NO971900D0 (en
Inventor
Dawn Smilek
Michael Samson
Malcolm Gefter
Di-Hwei Hsu
Jia-Dong Shi
Xavier Paliard
Brigitte Devaux
Jonathan Rothbard
Henry Franzen
Original Assignee
Immulogic Pharma Corp
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Immulogic Pharma Corp filed Critical Immulogic Pharma Corp
Publication of NO971900D0 publication Critical patent/NO971900D0/en
Publication of NO971900L publication Critical patent/NO971900L/en

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/705—Receptors; Cell surface antigens; Cell surface determinants
    • C07K14/70503—Immunoglobulin superfamily
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/19—Cytokines; Lymphokines; Interferons
    • A61K38/21—Interferons [IFN]
    • A61K38/215—IFN-beta
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/46—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates
    • C07K14/47—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates from mammals
    • C07K14/4701—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates from mammals not used
    • C07K14/4713—Autoimmune diseases, e.g. Insulin-dependent diabetes mellitus, multiple sclerosis, rheumathoid arthritis, systemic lupus erythematosus; Autoantigens

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Immunology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Zoology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Animal Behavior & Ethology (AREA)
  • Engineering & Computer Science (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Biophysics (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Molecular Biology (AREA)
  • Genetics & Genomics (AREA)
  • General Chemical & Material Sciences (AREA)
  • Biochemistry (AREA)
  • Toxicology (AREA)
  • Rheumatology (AREA)
  • Epidemiology (AREA)
  • Neurology (AREA)
  • Rehabilitation Therapy (AREA)
  • Hematology (AREA)
  • Diabetes (AREA)
  • Neurosurgery (AREA)
  • Biomedical Technology (AREA)
  • Cell Biology (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Peptides Or Proteins (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Nitrogen And Oxygen Or Sulfur-Condensed Heterocyclic Ring Systems (AREA)

Abstract

Det beskrives isolerte peptider og kombinasjoner av peptider avledet fra myelin- autoantigener slik som MBP, MOG, PLP og MAG egnet for behandling av multippel sklerose, inkludert profylaktiske og terapeutiske blandinger og fremgangsmåter for forhindring eller behandling av multippel sklerose. Foretrukne blandinger som beskrives omfatter i det minste et isolert, renset peptid fritt for alle andre peptider eller kontaminanter, peptidet omfatter en aminosyresekvens, myelinautoantigenet som har T-celle aktivitet. En terapeutisk blanding som beskrives er istand til å nedregulere autoantigenet med spesifikk immunrespons til myelinautoantigenet i en populasjon av mennesker som lider av eller er mottagelig for multippel sklerose slik at sykdomssymptomene reduseres, elimineres eller reverseres og/eller starten eller progresjonen av sykdomssymptomene forhindres eller nedsettes. I tillegg kan blandingene og fremgangsmåtene som beskrives, når administrert i et langtkommet stadium av sykdommen, reversere pågående paralyse eller andre tegn på syk- dommen når administrert under den akutte fasen av sykdommen eller forhindre tilbakefall når adminstrert under remisjon.Isolated peptides and combinations of peptides derived from myelin autoantigens such as MBP, MOG, PLP and MAG are suitable for the treatment of multiple sclerosis, including prophylactic and therapeutic compositions and methods for the prevention or treatment of multiple sclerosis. Preferred compositions disclosed include at least one isolated, purified peptide free from all other peptides or contaminants, the peptide comprising an amino acid sequence, the myelin autoantigen having T cell activity. A therapeutic composition described is capable of down-regulating the autoantigen with specific immune response to the myelin autoantigen in a population of people suffering from or susceptible to multiple sclerosis so that the disease symptoms are reduced, eliminated or reversed and / or the onset or progression of the disease symptoms prevented or decreased. In addition, the compositions and methods described, when administered at an advanced stage of the disease, may reverse ongoing paralysis or other signs of the disease when administered during the acute phase of the disease or prevent relapse when administered during remission.

NO971900A 1994-10-25 1997-04-24 Mixtures and treatment of multiple sclerosis NO971900L (en)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US32822494A 1994-10-25 1994-10-25
US40422895A 1995-03-15 1995-03-15
PCT/US1995/013682 WO1996012737A2 (en) 1994-10-25 1995-10-25 Compositions and treatment for multiple sclerosis

Publications (2)

Publication Number Publication Date
NO971900D0 NO971900D0 (en) 1997-04-24
NO971900L true NO971900L (en) 1997-06-25

Family

ID=26986277

Family Applications (1)

Application Number Title Priority Date Filing Date
NO971900A NO971900L (en) 1994-10-25 1997-04-24 Mixtures and treatment of multiple sclerosis

Country Status (15)

Country Link
EP (1) EP0787147A1 (en)
JP (1) JPH10504039A (en)
AU (1) AU4278296A (en)
BR (1) BR9509438A (en)
CA (1) CA2203629A1 (en)
CZ (1) CZ122697A3 (en)
FI (1) FI971750A7 (en)
HU (1) HUT77047A (en)
IL (1) IL115766A0 (en)
IS (1) IS4466A (en)
NO (1) NO971900L (en)
PL (1) PL324091A1 (en)
SI (1) SI9520118A (en)
SK (1) SK51297A3 (en)
WO (1) WO1996012737A2 (en)

Families Citing this family (22)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6252040B1 (en) * 1991-10-22 2001-06-26 The Governors Of The University Of Alberta Peptide specificity of anti-myelin basic protein and the administration of myelin basic protein peptides to multiple sclerosis patients
US6156535A (en) 1995-08-04 2000-12-05 University Of Ottawa Mammalian IAP gene family, primers, probes, and detection methods
DE69733343D1 (en) 1996-03-21 2005-06-30 Circassia Ltd CRYPTIC PEPTIDES AND METHOD FOR THEIR IDENTIFICATION
EP0939826A2 (en) * 1996-08-15 1999-09-08 Agrivax Incorporated Delivery of tolerogenic antigens via edible plants or plant-derived products
CA2494338C (en) * 1997-04-04 2007-07-17 The Governors Of The University Of Alberta Peptide specificity of anti-myelin basic protein and the administration of myelin basic protein peptides to multiple sclerosis patients
SE9703287D0 (en) * 1997-09-11 1997-09-11 Astra Ab Peptides
HK1039636A1 (en) * 1998-05-05 2002-05-03 科里克萨公司 Myelin basic protein peptides and uses thereof
US20020072493A1 (en) 1998-05-19 2002-06-13 Yeda Research And Development Co. Ltd. Activated T cells, nervous system-specific antigens and their uses
CA2328612A1 (en) * 1998-05-19 1999-11-25 Yeda Research And Development Co., Ltd. Activated t cells, nervous system-specific antigens and their uses
EP1288226A1 (en) * 2001-09-03 2003-03-05 Nederlandse Organisatie Voor Toegepast-Natuurwetenschappelijk Onderzoek Tno Modification of the expression levels of Toll-like receptor familiy members for influencing neurodegeneration and neuroprotection in the human central nervous system
GB0202399D0 (en) 2002-02-01 2002-03-20 Univ Bristol Peptide
WO2003080638A2 (en) 2002-03-27 2003-10-02 Aegera Therapeutics, Inc. Antisense iap nucleobase oligomers and uses thereof
DE10230381A1 (en) 2002-07-05 2004-01-22 Institut für Medizintechnologie Magdeburg GmbH, IMTM Use of inhibitors of alanyl aminopeptidases and pharmaceutical compositions comprising them
US8012944B2 (en) 2003-10-30 2011-09-06 Pharmascience Inc. Method for treating cancer using IAP antisense oligomer and chemotherapeutic agent
AU2007351813B2 (en) 2006-10-31 2013-10-10 East Carolina University Fusion proteins comprising an anti-inflammatory cytokine and an antigen for treatment of immune disorders
US8815794B2 (en) * 2008-08-28 2014-08-26 The Research Foundation For The State University Of New York Treatment of amyloidoses using myelin basic protein and fragments thereof
US20120082644A1 (en) * 2009-03-31 2012-04-05 Mannie Mark D Cytokines and neuroantigens for treatment of immune disorders
WO2011046462A1 (en) 2009-10-12 2011-04-21 Angport Limited Composition for treatment of multiple sclerosis
RU2448685C2 (en) * 2009-11-30 2012-04-27 Российская Федерация в лице Министерства промышленности и торговли Российской Федерации Liposomes containing oligopeptides - fragments of myelin basic protein, pharmaceutical composition and method of treating multiple sclerosis
CA2830772C (en) 2011-03-21 2020-04-28 Atlantic Cancer Research Institute Polypeptides with affinity for heat shock proteins (hsps) and hsp associated complexes (hacs) and their use in diagnosis and therapy
AU2015204452A1 (en) 2014-01-13 2016-08-11 Berg Llc Enolase 1 (Eno1) compositions and uses thereof
CN108884140B (en) 2015-12-03 2022-10-25 朱诺治疗学股份有限公司 Modified chimeric receptors and related compositions and methods

Family Cites Families (21)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DE3856566T2 (en) * 1987-06-24 2004-06-24 Brigham And Women's Hospital, Boston Treatment of autoimmune diseases by oral administration of autoantigens
US5260422A (en) * 1988-06-23 1993-11-09 Anergen, Inc. MHC conjugates useful in ameliorating autoimmunity
WO1991008760A1 (en) * 1989-12-20 1991-06-27 Brigham And Women's Hospital Improved treatment of autoimmune diseases by aerosol administration of auto antigens
DE69127470T2 (en) * 1990-03-02 1998-02-19 Autoimmune Inc REINFORCING REGULATION OF AUTOIMMUNE DISEASES BY ORAL OR ENTERAL ADMINISTRATION OF AUTOANTIGENS
IL97709A (en) * 1990-03-30 2005-05-17 Brigham & Womens Hospital Use of an mbp peptide for the preparation of a medicament for the treatment of multiple sclerosis
CA2053799C (en) * 1991-10-22 2002-03-12 Kenneth G. Warren Synthetic peptide specificity of anti-myelin basic protein from multiple sclerosis cerebrospinal fluid
JPH07501526A (en) * 1991-11-19 1995-02-16 アナージェン，インコーポレイティド MHC subunit conjugates useful in ameliorating adverse immune responses
ES2190784T3 (en) * 1992-02-28 2003-08-16 Autoimmune Inc SUPPRESSION OF AUTOIMMUNE DISEASES BY SPECTING ANTIGENS.
IL105153A (en) * 1992-03-25 1999-12-22 Immulogic Pharma Corp Therapeutic compositions comprising peptides derived from human t cell reactive feline protein
WO1993021222A1 (en) * 1992-04-09 1993-10-28 Autoimmune, Inc. Suppression of t-cell proliferation using peptide fragments of myelin basic protein
WO1993025661A1 (en) * 1992-06-10 1993-12-23 President And Fellows Of Harvard College Heterogeneous proteolipid peptide 139-151-specific t cell clones
IL106720A (en) * 1992-08-17 1998-10-30 Autoimmune Inc Use of a bystander antigen to prepare compositions for treating retroviral-associated neurological disease in a mammal and such compositions
CA2170901A1 (en) * 1993-09-03 1995-03-09 Brigitte Devaux Uses of myelin oligodendrocyte glycoprotein and peptide portions thereof in protocols related to autoimmune disease
WO1995007096A1 (en) * 1993-09-06 1995-03-16 La Trobe University Treatment of autoimmune disease
CA2172512A1 (en) * 1993-09-22 1995-03-30 Lawrence Steinman Interaction of t-cell receptors and antigen in autoimmune disease
BR9507452A (en) * 1994-04-08 1997-08-05 Brigham & Womens Hospital Pharmaceutical composition use of a non-interferon polypeptide use of a quantity of a standardized antigen and a quantity of a non-interferon polypeptide and product containing (1) a quantity of a standardized antigen and (11) a quantity of a non-interferon polypeptide
JPH09511745A (en) * 1994-04-08 1997-11-25 ブリガム アンド ウィミンズ ホスピタル Treatment of autoimmune diseases with oral tolerance and/or type I interferon
HUT76099A (en) * 1994-05-10 1997-06-30 Immulogic Pharma Corp Compositions and treatment for multiple sclerosis
CA2192468A1 (en) * 1994-06-09 1995-12-14 Johannes M. Van Noort Alpha b crystallin for use in diagnosis and therapy of auto-immune diseases in particular multiple sclerosis
US6329499B1 (en) * 1994-11-18 2001-12-11 Neurocrine Biosciences, Inc. Methods for treatment of multiple sclerosis using peptide analogues of human myelin basic protein
DE69525544T2 (en) * 1994-11-18 2002-08-22 Neurocrine Biosciences, Inc. PEPTIDE ANALOGUE OF THE HUMAN MYELINE-BASED PROTEIN WITH SUBSTITUTION IN POSITION 91 FOR TREATING MULTIPLE Sclerosis

Also Published As

Publication number Publication date
FI971750A0 (en) 1997-04-24
CA2203629A1 (en) 1996-05-02
FI971750A7 (en) 1997-06-24
PL324091A1 (en) 1998-05-11
WO1996012737A3 (en) 1996-10-10
HUT77047A (en) 1998-03-02
SK51297A3 (en) 1998-03-04
EP0787147A1 (en) 1997-08-06
CZ122697A3 (en) 1997-09-17
WO1996012737A2 (en) 1996-05-02
IS4466A (en) 1997-04-17
SI9520118A (en) 1998-08-31
JPH10504039A (en) 1998-04-14
NO971900D0 (en) 1997-04-24
IL115766A0 (en) 1996-01-19
BR9509438A (en) 1997-12-23
AU4278296A (en) 1996-05-15

Similar Documents

Publication Publication Date Title
WO1996012737A3 (en) Compositions and treatment for multiple sclerosis
Neufeld et al. Two types of autoimmune Addison's disease associated with different polyglandular autoimmune (PGA) syndromes
RU2007102698A (en) COMPOSITIONS AND METHODS OF TREATING NEUROLOGICAL DISORDERS
Polman et al. Low-dose cyclosporin A induces relapsing remitting experimental allergic encephalomyelitis in the Lewis rat
RU94046424A (en) Method of separation of dna-ase forms, human dna-ase, pharmaceutical composition, method of dna-ase storage, treatment method
US4818763A (en) Biologically active substance with hormonal properties, production process thereof and utilization of histones for medical purposes
ATE415173T1 (en) PAN DR BINDING PROTEINS TO INCREASE THE IMMUNE RESPONSE
KR0159046B1 (en) Treatment of autoimmune diseases by aerosol administration of autoantigens
EP1918298A3 (en) Peptide
Katayama et al. Potential of plant-derived peptides for the improvement of memory and cognitive function
Petrov et al. Bone marrow immunoregulatory peptides (myelopeptides): isolation, structure, and functional activity
WO1995030435A3 (en) Compositions and treatment for multiple sclerosis
NO964199L (en) Treatment of autoimmune disease using oral tolerance and / or type I interferon
Padrós et al. Mitogenic activation of the human lymphocytes induce the release of proenkephalin derived peptides
Yamada et al. Bombesin-like immunoreactivity in human cerebrospinal fluid
KR20080098488A (en) HIV treatment
Kaneko et al. Purification and identification of endogenous anti-opioid substances from bovine brain
US20080207500A1 (en) Medicament
Kang et al. Fulminating systemic capillary leak syndrome with lymphocytosis and hypogammaglobulinemia
Geovese et al. Giardiasis as a cause of hypokalemic myopathy in congenital immunodeficiency
Oyaizu et al. Lambert-Eaton myasthenic syndrome associated with an anterior mediastinal small cell carcinoma
EP1427755A2 (en) Use of peptides comprising post-translational modifications in the treatment of autoimmune pathologies
Strian et al. Anxiety Depression in Affective Disorders
Kastin et al. DSIP-like immunoreactivity in the developing rat brain
Cotton Options for Multiple Sclerosis Therapy